BMY vs. MRK, ABBV, PFE, ZTS, RPRX, JAZZ, PRGO, CORT, SUPN, and PCRX
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Merck & Co., Inc. (MRK), AbbVie (ABBV), Pfizer (PFE), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), and Pacira BioSciences (PCRX). These companies are all part of the "pharmaceuticals" industry.
Bristol-Myers Squibb (NYSE:BMY) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.
Bristol-Myers Squibb currently has a consensus target price of $60.00, indicating a potential upside of 48.18%. Merck & Co., Inc. has a consensus target price of $131.33, indicating a potential upside of 4.14%. Given Bristol-Myers Squibb's higher possible upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Merck & Co., Inc..
Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.9%. Merck & Co., Inc. pays an annual dividend of $3.08 per share and has a dividend yield of 2.4%. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 342.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.
Bristol-Myers Squibb received 112 more outperform votes than Merck & Co., Inc. when rated by MarketBeat users. However, 66.97% of users gave Merck & Co., Inc. an outperform vote while only 66.89% of users gave Bristol-Myers Squibb an outperform vote.
Bristol-Myers Squibb has higher earnings, but lower revenue than Merck & Co., Inc.. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.
76.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.1% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Bristol-Myers Squibb had 14 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 36 mentions for Bristol-Myers Squibb and 22 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 1.25 beat Bristol-Myers Squibb's score of 0.54 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.
Merck & Co., Inc. has a net margin of 3.76% compared to Bristol-Myers Squibb's net margin of -13.50%. Merck & Co., Inc.'s return on equity of 14.05% beat Bristol-Myers Squibb's return on equity.
Bristol-Myers Squibb has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.
Summary
Merck & Co., Inc. beats Bristol-Myers Squibb on 11 of the 19 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
